Scilex sells 4% royalty on Gloperba/Elyxyb to defer Tranche B amortization to 2026

Scilex Holding Co

Sold 4% of aggregate net sales of Gloperba and Elyxyb to Oramed, Murchinson, and 3i; consideration is deferral of First Amortization Payment on Tranche B Notes to Oct 8, 2026.
Entered Security Agreement granting first-priority liens on royalty collateral; Note Agent's lien subordinated to second priority.
Licensed exclusive worldwide ex-US rights to Gloperba to RoyaltyVest Ltd on 50/50 net revenue split.
Amended ZTlido Royalty Agreement to allow asset sale without consent if all Debt Instrument obligations are paid in full.
Transaction closed Feb 28, 2025; grants Royalty and Exclusive Rights under January 2, 2025 Tranche B Consents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.